 Halozyme Therapeutics Inc NASDAQ: HALO reported Q2 revenue of 136.5 million compared to 55.2 million a year ago, beating the consensus of 103.16 million. The increase was primarily driven by 60.0 million in milestone revenues, including 40 million from ViiV and 20 million from Janssen earned upon achieving a commercial milestone related to subcutaneous Darzalex, an increase in royalty revenue from subcutaneous Darzalex, and an increase in product sales. 